Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Cancer develops by accumulation of somatic driver mutations, which impact cellular function. Mutations in non-coding regulatory regions can now be studied genome-wide and further characterized by correlation with gene expression and clinical outcome to identify driver candidates. Using a new two-stage procedure, called ncDriver, we first screened 507 ICGC whole-genomes from 10 cancer types for non-coding elements, in which mutations are both recurrent and have elevated conservation or cancer specificity. This identified 160 significant non-coding elements, including the TERT promoter, a well-known non-coding driver element, as well as elements associated with known cancer genes and regulatory genes (e.g., PAX5 , TOX3 , PCF11 , MAPRE3 ). However, in some significant elements, mutations appear to stem from localized mutational processes rather than recurrent positive selection in some cases. To further characterize the driver potential of the identified elements and shortlist candidates, we identified elements where presence of mutations correlated significantly with expression levels (e.g., TERT and CDH10 ) and survival (e.g., CDH9 and CDH10 ) in an independent set of 505 TCGA whole-genome samples. In a larger pan-cancer set of 4128 TCGA exomes with expression profiling, we identified mutational correlation with expression for additional elements (e.g., near GATA3 , CDC6 , ZNF217 , and CTCF transcription factor binding sites). Survival analysis further pointed to MIR122 , a known marker of poor prognosis in liver cancer. In conclusion, the screen for significant mutation patterns coupled with correlative mutational analysis identified new individual driver candidates and suggest that some non-coding mutations recurrently affect expression and play a role in cancer development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 5×
“Each tested element was associated to the nearest gene, and the test was based on gene expression in an independent set of 7382 RNAseq samples of which 4128 had paired exome mutation calls (both SNVs and INDELs).(16) Though the power to call mutations from exome capture data is highest in protein-coding regions, 50% o…”
MethodInfluentialBootstrap Methods and their Application
Davison, A. C., & Hinkley, D. V. (1997) · doi:10.1017/cbo9780511802843 · Cited by 7,350
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585 · cited 2×
“1b, c).(17,18) Protein-coding genes (n = 20,020; 1.”
MethodSelf-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“Driver recall in known cancer genes were evaluated by the number of genes, associated with significant elements, that overlap genes in the COSMIC Gene Census database version 76.(73) Significance of observed enrichments were calculated using Fisher’s exact test for two-times-two contingency tables (Supplementary Table…”
MethodOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“It mediates oncogenic activity through repression of the INK4/ARF tumor suppressor pathway(48) and is an activator of oncogenic senescence.(49) In breast cancer, its expression correlates with poor prognosis.”
BackgroundTERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 6×
“The best-studied example is the TERT promoter, with frequent mutations in melanoma and other cancer types that increase expression in cellular assays.(8,9) A few other cases of noncoding drivers have been reported, including splice site mutations in TP53 and GATA3,(10,11) as well as mutations in a distal PAX5 enhancer…”
BackgroundInfluential
Cited by
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
Rheinbay, E., Nielsen, M. M., Abascal, F., Wala, J. A., Shapira, O., Tiao, G., Hornshøj, H., Hess, J. M., Juul, R. I., Lin, Z., et al. (2020) · Nature · doi:10.1038/s41586-020-1965-x · Cited by 602
Self-citationGenome-wide somatic alterations in multiple myeloma reveal a superior outcome group
Samur, M. K., Aktas Samur, A., Fulciniti, M., Szalat, R., Han, T., Shammas, M., Richardson, P., Magrangeas, F., Minvielle, S., Corre, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00461 · Cited by 70
Consequences of genetic variants in miRNA genes
Machowska, M., Galka-Marciniak, P., & Kozlowski, P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.036 · Cited by 40
“MIR122 has also been detected as an overmutated potential cancer driver in liver carcinoma in others genome wide studies utilizing different cancer driver identification strategies [156,157].”
BackgroundNavigating the non-coding genome in heart development and Congenital Heart Disease
Chahal, G., Tyagi, S., & Ramialison, M. (2019) · Differentiation · doi:10.1016/j.diff.2019.05.001 · Cited by 31
Metadata
- Authors
- Hornshøj, H., Nielsen, M. M., Sinnott-Armstrong, N. A., Świtnicki, M. P., Juul, M., Madsen, T., Sallari, R., Kellis, M., Ørntoft, T., Hobolth, A., & Pedersen, J. S.
- Venue
- npj Genomic Medicine
- Published
- 2018-01-11
- Volume
- 3
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2056-7944 (ISSN-L)
- OpenAlex
- W2951026093
- Cited by
- 74
- References
- 17
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. https://app.cochat.ai/papers/10.1038/s41525-017-0040-5
- The paper
- Hornshøj, H., Nielsen, M. M., Sinnott-Armstrong, N. A., Świtnicki, M. P., Juul, M., Madsen, T., Sallari, R., Kellis, M., Ørntoft, T., Hobolth, A., & Pedersen, J. S. (2018). Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. npj Genomic Medicine. https://doi.org/10.1038/s41525-017-0040-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.